Breakpoints cover image

#67 – Nixing the Nidus: Managing Retained Sources in Prosthetic Joint Infections

Breakpoints

00:00

Refampin and TB

The two big issues are the interacting antiflatelet therapies and therapeutic gannic coagulation that the patient really needs like for a hard valve or pulmonary embolism. I'm also cautious about adding it in patients who have severe liver disease because the potential for additive hepatotoxicity. Unplanned refampin discontinuation in PGI treatment is not rare at all, so maybe I'm a coward but I remain hesitant about adding in that situation.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app